Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Basic science

1802MO - Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort

Date

19 Sep 2021

Session

Mini oral session - Basic science

Topics

Basic Science

Tumour Site

Presenters

Letizia Gnetti

Citation

Annals of Oncology (2021) 32 (suppl_5): S1227-S1236. 10.1016/annonc/annonc681

Authors

L. Gnetti1, F. Negri2, L. Bottarelli3, N. Campanini1, M.E. Negru4, F. Bergamo5, M. Frisinghelli6, G. Chiaulon7, A. Tagliagambe8, A. Morabito9, V. Smiroldo10, G.A.C. Vita11, S. Tamberi12, S.S. Cordio13, E.M. Silini1, C. Azzoni14, F. Gaiani15, G.L. de’Angelis16, L. Boni17, C. aschele18

Author affiliations

  • 1 Pathology, Azienda Ospedaliero-Universitaria di Parma, 43126 - Parma/IT
  • 2 Oncology, AOU di Parma, 43126 - Parma/IT
  • 3 Pathology, University Hospital of Parma, Parma/IT
  • 4 Oncology, Azienda Ospedaliera Maggiore Della Carità, 28100 - Novara/IT
  • 5 Dipartimento Oncologia 1, IOV - Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 6 Oncology Department, Ospedale Santa Chiara - APSS, 38122 - Trento/IT
  • 7 Radioterapia, Azienda Sanitaria Universitaria Integrata, Udine/IT
  • 8 Radiotherapy, Ospedale di Carrara, Carrara/IT
  • 9 Oncology Department, Ospedale Civile, 35012 - Camposampiero/IT
  • 10 Medical Oncology And Hematology Unit, Humanitas Cancer Center, Irccs Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy, Milan/IT
  • 11 Pathology, IRCCS Centro di Riferimento Oncologico Della Basilicata (CROB), Rionero in Vulture/IT
  • 12 Oncology Department, Ospedale degli Infermi, 48018 - Faenza/IT
  • 13 Oncology, Azienda Ospedaliera ARNAS Garibaldi, 95100 - Catania/IT
  • 14 Medicine And Surgery, Università Degli Studi Di Parma - Facoltà di Medicina e Chirurgia, 43125 - Parma/IT
  • 15 Gastroenterology Unit, Azienda Ospedaliero-Universitaria di Parma di Parma, Parma/IT
  • 16 Oncology Unit, Azienda Ospedaliero-Universitaria di Parma di Parma, 43126 - Parma/IT
  • 17 Epidemiologia Clinica, Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 18 Oncology, Ospedale Civile Sant'Andrea di La Spezia - ASL5 Spezzino, 19124 - la spezia/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1802MO

Background

Preoperative chemoradiotherapy (CRT) may increase antitumor immunity through enhancing T-cell activation and tumor infiltration. These effects could possibly sensitize tumours to immunotherapies, including checkpoint inhibitors. We explored whether preoperative CRT for locally advanced rectal cancer (LARC) induces immunologic changes and if the post-operative biological parameters are associated with tumour regression grade (TRG sec. Ryan –AJCC Eight ed.).

Methods

The multicenter randomized STAR-01 study compared a standard preoperative CRT regimen (50.4 Gy in 28 daily fractions with concomitant infused fluorouracil at the dose of 225 mg/m2/d) with the same regimen plus oxaliplatin given weekly at the dose of 60 mg/m2 in patients with LARC. Paired pre- and post-operative specimens were available for 81 patients and were analyzed by immunohistochemistry. The immunoistochemical analysis was performed with a panel of immune cells and associated factors as CD3, CD20, CD4/CD8, PD1. The pattern of tumor infiltrating lymphocytes (TILs) and related infiltrating lymphocytes (RILs) was also evaluated. Response to pre-operative chemoradiotherapy was assessed according to TRG.

Results

After therapy we observed a decreased CD4/CD8 ratio (p <0.001) and reduced expression level of CD20 (p<0.001). The expression level of CD3+ and PD-1+ cells after therapy did not change significantly. The relative increase of lymphocytes CD8+ inside CD4/CD8 ratio evaluated on post-operative samples was significantly associated with TRG 0 (p<0.001).

Conclusions

Our data suggest that CRT may induce an enrichment of CD8+ T lymphocytes and this translates in better response to CRT. The new frontier of best treatment could be the use of specific immune cells (T lymphocytes) to trigger the system's immune response against disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University Hospital of Parma.

Funding

SNUPI ONLUS.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.